Abstract
There is a rapid expansion in the number of new anti-cancer drugs with remarkably different mechanisms of action that can augment traditional chemotherapy. As these agents are often used in combination with traditional chemotherapy testing the effects of these novel agents has proven difficult requiring large sample sizes to detect relatively small differences in patient survival. Despite the wide variety of mechanisms, most new drugs are thought to ultimately induce apoptosis of tumor cells or their supportive vasculature. Imaging agents that can non-invasively monitor apoptosis in response to these new drugs could therefore help streamline the drug development process. They may also help guide oncologists to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug. In this article we will outline the existing imaging agents and modalities that are currently undergoing clinical testing and those that could be rapidly translated into humans.
Anti-Cancer Agents in Medicinal Chemistry
Title: Apoptosis Imaging: Anti-Cancer Agents in Medicinal Chemistry
Volume: 9 Issue: 9
Author(s): Francis G. Blankenberg
Affiliation:
Keywords: Apoptosis, SPECT, PET, MRI, oncology
Abstract: There is a rapid expansion in the number of new anti-cancer drugs with remarkably different mechanisms of action that can augment traditional chemotherapy. As these agents are often used in combination with traditional chemotherapy testing the effects of these novel agents has proven difficult requiring large sample sizes to detect relatively small differences in patient survival. Despite the wide variety of mechanisms, most new drugs are thought to ultimately induce apoptosis of tumor cells or their supportive vasculature. Imaging agents that can non-invasively monitor apoptosis in response to these new drugs could therefore help streamline the drug development process. They may also help guide oncologists to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug. In this article we will outline the existing imaging agents and modalities that are currently undergoing clinical testing and those that could be rapidly translated into humans.
Export Options
About this article
Cite this article as:
Blankenberg G. Francis, Apoptosis Imaging: Anti-Cancer Agents in Medicinal Chemistry, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/187152009789377727
DOI https://dx.doi.org/10.2174/187152009789377727 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Current Molecular Pharmacology Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy
Current Medicinal Chemistry Targeting the Most Upstream Site of Wnt Signaling Pathway Provides a Strategic Advantage for Therapy in Colorectal Cancer
Current Drug Targets Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment
Current Medicinal Chemistry Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Decreased Expression of MYPT1 Contributes to Tumor Angiogenesis and Poor Patient Prognosis in Human Prostate Cancer
Current Molecular Medicine PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies
Reviews on Recent Clinical Trials Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy
Current Pharmaceutical Design Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets Combination Therapy with Hepatocyte Growth Factor and Oseltamivir Confers Enhanced Protection Against Influenza Viral Pneumonia
Current Molecular Medicine Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Cancer Regulator MicroRNA: Potential Relevance in Diagnosis, Prognosis and Treatment of Cancer
Current Medicinal Chemistry Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine